Drugs / NP001
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03179501 | Sep 2017 → Jul 2018 | Alzheimer disease | Beau Nakamoto | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01091142 | Jul → Sep 2010 | amyotrophic lateral sclerosis | Neuraltus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01281631 | Feb 2011 → Sep 2012 | amyotrophic lateral sclerosis | Neuraltus Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NP001 | “This study is a double-blind, placebo-controlled single ascending dose safety and tolerability study. Approximately 32-56 subjects with clinical diagnosis of ALS according to...” NCT01091142 ↗ |
| Known as | sodium chlorite | “the innate immune modulator NP001 (a pH-adjusted intravenous formulation of purified sodium chlorite)” PMID 39457678 ↗ Oct 2024 |
| Route | Intravenous | “Drug or placebo will be given intravenously.” NCT01281631 ↗ |